Hopes of a bright new future in stroke risk management in AF were dashed when asundexian failed against apixaban in the ...

A recent study published in JAMA has raised concerns about the safety of certain blood pressure medications for patients with ...

A new study shows that the US is still behind in controlling the price of prescription drugs. One doctor explains why America ...

The results of the ROCKET AF trial provide clear and convincing evidence for the efficacy and safety of rivaroxaban compared ... of this manuscript. Atrial fibrillation (AF) is the most common ...

This includes Xarelto, which is manufactured by Johnson and Johnson to treat atrial fibrillation; Eliquis, which is ...

Clinical question: How effective and safe are apixaban versus rivaroxaban versus warfarin in patients with cirrhosis and nonvalvular atrial fibrillation (AF)? Background: Apixaban, rivaroxaban, and ...

Clinical question: Do patients with carotid artery plaque containing detectable microplastics and nanoplastics (MNPs) have a higher risk of myocardial infarction, stroke, or death? Background: Plastic ...

Younger patients with the common heart rhythm disorder atrial fibrillation but no other risk factors for stroke are not likely ... Half of them received 15 milligrams daily of rivaroxaban, sold by ...

A Canadian study has shed new light on the treatment of younger atrial fibrillation patients. The research, unveiled at the American Heart Association Scientific Sessions in Chicago, indicates that ...

Request permissions for this article. Department of Pharmacology and Cancer Biology, Duke University, Durham, NC. (C.V.C., H.Y., B.A.S.) Department of Surgery, Duke ...

Younger patients with the common heart rhythm disorder atrial fibrillation but no other risk ... (JNJ.N), opens new tab under the brand name Xarelto. The others received a placebo.